The BATTLE trial: personalizing therapy for lung cancer.
نویسندگان
چکیده
UNLABELLED The Biomarker-integrated Approaches of Targeted Therapy for Lung Cancer Elimination (BATTLE) trial represents the first completed prospective, biopsy-mandated, biomarker-based, adaptively randomized study in 255 pretreated lung cancer patients. Following an initial equal randomization period, chemorefractory non-small cell lung cancer (NSCLC) patients were adaptively randomized to erlotinib, vandetanib, erlotinib plus bexarotene, or sorafenib, based on relevant molecular biomarkers analyzed in fresh core needle biopsy specimens. Overall results include a 46% 8-week disease control rate (primary end point), confirm prespecified hypotheses, and show an impressive benefit from sorafenib among mutant-KRAS patients. BATTLE establishes the feasibility of a new paradigm for a personalized approach to lung cancer clinical trials. SIGNIFICANCE The BATTLE study is the first completed prospective, adaptively randomized study in heavily pretreated NSCLC patients that mandated tumor profiling with "real-time" biopsies, taking a substantial step toward realizing personalized lung cancer therapy by integrating real-time molecular laboratory findings in delineating specific patient populations for individualized treatment.
منابع مشابه
The BATTLE Trial : Personalizing Therapy for Lung Cancer Cancer
Edward S. Kim*, Roy S. Herbst*, Ignacio I. Wistuba*, J. Jack Lee*, George R. Blumenschein Jr, Anne Tsao, David J. Stewart, Marshall E. Hicks, Jeremy Erasmus Jr, Sanjay Gupta, Christine M. Alden, Suyu Liu, Ximing Tang, Fadlo R. Khuri, Hai T. Tran, Bruce E. Johnson, John V. Heymach, Li Mao, Frank Fossella, Merrill S. Kies, Vassiliki Papadimitrakopoulou, Suzanne E. Davis, Scott M. Lippman1,†, and ...
متن کاملA new BATTLE in the evolving war on cancer.
The Biomarker-integrated Approaches of Targeted Therapy for Lung Cancer Elimination (BATTLE) trial couples real-time molecular interrogation of cancer specimens with an adaptive Bayesian clinical trial design.
متن کاملCotargeting cyclin D1 starts a new chapter in lung cancer prevention and therapy.
Lung cancer has limited effective therapy and no effective prevention. Cytotoxic chemotherapy has not improved when combined with the epidermal growth factor receptor (EGFR) inhibitor erlotinib (standard lung cancer therapy) or with the rexinoid bexarotene. Combining erlotinib and bexarotene, however, to cotarget cyclin D1 via the retinoid X receptor and EGFR was active preclinically in KRAS-dr...
متن کاملThe BATTLE to personalize lung cancer prevention through reverse migration.
Agents can enter clinical development for cancer prevention either initially or after previous development for a different indication, such as arthritis, with both approaches consuming many years of development before an agent is fully evaluated for cancer prevention. We propose the following, third approach: reverse migration, that is, importing agents, targets, and study designs to personaliz...
متن کاملThe BATTLE trial: a bold step toward improving the efficiency of biomarker-based drug development.
Successful completion of the Biomarker-integrated Approaches of Targeted Therapy for Lung Cancer Elimination (BATTLE) trial, reported in this issue of Cancer Discovery, is an important advance in the effort to improve clinical trial approaches to the simultaneous development of new therapeutics with matching diagnostic tests so that patients most likely to benefit from these therapies can be id...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- Cancer discovery
دوره 1 1 شماره
صفحات -
تاریخ انتشار 2011